Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients
| Autor: | Yongxin Bao, Wanjun Kang, Fubin Jiao, Yinghuan Ma, Yiran Ma |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Cardiac function curve
Adult medicine.medical_specialty Pathology Serum albumin lcsh:Medicine Breast Neoplasms Serum Albumin Human Creatine Gastroenterology chemistry.chemical_compound Breast cancer Troponin T Internal medicine medicine Creatine Kinase MB Form Humans Doxorubicin lcsh:Science Serum Albumin Aged Multidisciplinary Ejection fraction biology business.industry lcsh:R Albumin Middle Aged medicine.disease Prognosis chemistry Heart Injuries ROC Curve biology.protein Female lcsh:Q business Biomarkers medicine.drug Research Article |
| Zdroj: | PLoS ONE, Vol 8, Iss 11, p e79426 (2013) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Background Ischemia-modified albumin is an altered serum albumin that forms under conditions of oxidative stress, a state also associated with doxorubicin-induced myocardial injury. Objective The aim of this study was to better assess diagnostic and prognostic significance of ischemia-modified albumin in patients with breast cancer undergoing doxorubicin chemotherapy. Methods Blood samples were collected from 152 breast cancer patients before and after each cycle of doxorubicin chemotherapy to measure the serum levels of ischemia-modified albumin, cardiac troponin T and creatine kinase-MB. We also monitored cardiac function during a 12 month follow-up. Results There was a significant difference in ischemia-modified albumin levels before and after each cycle of chemotherapy and the ischemia-modified albumin concentration positively correlated with the cumulative dose of doxorubicin (r = 0.212, P < 0.05). The combination of ischemia-modified albumin with cardiac troponin T and creatine kinase-MB increased the sensitivity to 0.920 and the specificity to 0.830 in the diagnosis of doxorubicin-induced myocardial injury. The optimal cutoff for ischemia-modified albumin concentration was 112.09 U/ml. The rate of change for ischemia-modified albumin levels correlated negatively with the rate of change for left ventricular ejection fraction at one year (r = –0.221, P < 0.05). Conclusion Ischemia-modified albumin may be a clinically potential new marker for diagnosing doxorubicin-induced myocardial injury, and is helpful to predict long-term impairment of cardiac function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|